MedTrace Logo

Ashwagandha for Cognitive Dysfunction

NCT04092647 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-06-15

No results posted yet for this study

Summary

This is a 1:1 randomized double blinded placebo controlled trial. • To determine if ashwagandha can improve cognitive dysfunction when compared with placebo in patients undergoing chemotherapy for cancer.

Conditions

  • Chemo Fog

Interventions

DRUG

Ashwagandha

Ashwagandha 350 mg po BID

DRUG

Placebo

Placebo 350 mg po BID

Sponsors & Collaborators

  • Sutter Health

    lead OTHER

Principal Investigators

  • Deepti Behl, MD · Sutter Health

  • Carol Parise, PhD · Sutter Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-12-31
Completion
2025-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04092647 on ClinicalTrials.gov